BioCentury | Dec 4, 2018
Finance

INKEF’s creative ambitions

...for European healthcare companies including bispecific antibody company F-Star Biotechnology Ltd. and multiple sclerosis company Canbex Therapeutics Ltd....
BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

...testing. (A) In Phase I/II testing; (B) In-licensed from 3B Pharmaceuticals GmbH ; (C) Partner Canbex Therapeutics Ltd....
...2015 gave Ipsen 177Lu- OPS201 , a radiopharmaceutical in Phase I/II testing. The same year, Canbex Therapeutics Ltd....
...AB (SSE:ACTI), Lund, Sweden Allergan plc (NYSE:AGN), Dublin, Ireland Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Canbex Therapeutics Ltd....
BioCentury | Jun 29, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

...School Distillery Therapeutics Musculoskeletal Spasticity Potassium calcium-activated channel subfamily M regulatory β subunit 4 (KCNMB4) Canbex Therapeutics Ltd....
...channel activator targeting KCNMB4, in Phase II testing to treat spasticity in multiple sclerosis patients. Canbex Therapeutics Ltd....
BioCentury | Nov 16, 2015
Clinical News

VSN16R: Phase II started

...Pink:IPSEY, Boulogne-Billancourt, France) has an exclusive option to acquire Canbex upon completion of the trial. Canbex Therapeutics Ltd....
BioCentury | Mar 9, 2015
Company News

Canbex Therapeutics, Ipsen deal

...of clinical trials or financial details. Ipsen did not respond to requests for more details. Canbex Therapeutics Ltd....
BioCentury | Mar 10, 2014
Company News

Canbex Therapeutics management update

Canbex Therapeutics Ltd. , London, U.K. Business: Autoimmune, Musculoskeletal Hired: Alberto Lledo as CMO; he replaces Miroslav Ravic WIR Staff autoimmune Musculoskeletal...
BioCentury | Nov 11, 2013
Clinical News

VSN16R: Phase I started

...I trial to evaluate single and multiple ascending-doses of VSN16R in about 72 healthy volunteers. Canbex Therapeutics Ltd....
BioCentury | May 20, 2013
Finance

Merck Serono's earnest money

...Germany Neviah Genomics Ltd. , Yavne, Israel Tables MS Ventures portfolio Company Description Raised Syndicate Canbex Therapeutics Ltd....
BioCentury | Apr 15, 2013
Financial News

Canbex Therapeutics completes venture financing

Canbex Therapeutics Ltd. , London, U.K. Business: Autoimmune, Musculoskeletal Date completed: 4/8/13 Type: Venture financing Raised: £2.1 million ($3.2 million) Investors: Merck Serono Ventures; UCL Business; Wellcome Trust Note: The amount raised includes undisclosed funding from...
BioCentury | Apr 15, 2013
Company News

Canbex Therapeutics board of directors update

Canbex Therapeutics Ltd. , London, U.K. Business: Autoimmune, Musculoskeletal Appointed: Nilesh Kumar, director at Merck Serono Ventures WIR Staff autoimmune Musculoskeletal...
Items per page:
1 - 10 of 11
BioCentury | Dec 4, 2018
Finance

INKEF’s creative ambitions

...for European healthcare companies including bispecific antibody company F-Star Biotechnology Ltd. and multiple sclerosis company Canbex Therapeutics Ltd....
BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

...testing. (A) In Phase I/II testing; (B) In-licensed from 3B Pharmaceuticals GmbH ; (C) Partner Canbex Therapeutics Ltd....
...2015 gave Ipsen 177Lu- OPS201 , a radiopharmaceutical in Phase I/II testing. The same year, Canbex Therapeutics Ltd....
...AB (SSE:ACTI), Lund, Sweden Allergan plc (NYSE:AGN), Dublin, Ireland Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Canbex Therapeutics Ltd....
BioCentury | Jun 29, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

...School Distillery Therapeutics Musculoskeletal Spasticity Potassium calcium-activated channel subfamily M regulatory β subunit 4 (KCNMB4) Canbex Therapeutics Ltd....
...channel activator targeting KCNMB4, in Phase II testing to treat spasticity in multiple sclerosis patients. Canbex Therapeutics Ltd....
BioCentury | Nov 16, 2015
Clinical News

VSN16R: Phase II started

...Pink:IPSEY, Boulogne-Billancourt, France) has an exclusive option to acquire Canbex upon completion of the trial. Canbex Therapeutics Ltd....
BioCentury | Mar 9, 2015
Company News

Canbex Therapeutics, Ipsen deal

...of clinical trials or financial details. Ipsen did not respond to requests for more details. Canbex Therapeutics Ltd....
BioCentury | Mar 10, 2014
Company News

Canbex Therapeutics management update

Canbex Therapeutics Ltd. , London, U.K. Business: Autoimmune, Musculoskeletal Hired: Alberto Lledo as CMO; he replaces Miroslav Ravic WIR Staff autoimmune Musculoskeletal...
BioCentury | Nov 11, 2013
Clinical News

VSN16R: Phase I started

...I trial to evaluate single and multiple ascending-doses of VSN16R in about 72 healthy volunteers. Canbex Therapeutics Ltd....
BioCentury | May 20, 2013
Finance

Merck Serono's earnest money

...Germany Neviah Genomics Ltd. , Yavne, Israel Tables MS Ventures portfolio Company Description Raised Syndicate Canbex Therapeutics Ltd....
BioCentury | Apr 15, 2013
Financial News

Canbex Therapeutics completes venture financing

Canbex Therapeutics Ltd. , London, U.K. Business: Autoimmune, Musculoskeletal Date completed: 4/8/13 Type: Venture financing Raised: £2.1 million ($3.2 million) Investors: Merck Serono Ventures; UCL Business; Wellcome Trust Note: The amount raised includes undisclosed funding from...
BioCentury | Apr 15, 2013
Company News

Canbex Therapeutics board of directors update

Canbex Therapeutics Ltd. , London, U.K. Business: Autoimmune, Musculoskeletal Appointed: Nilesh Kumar, director at Merck Serono Ventures WIR Staff autoimmune Musculoskeletal...
Items per page:
1 - 10 of 11